ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Folic Acid

Also written as “Norgestimate; Ethinyl Estradiol; Folic acid”, “Vitamin B12, Vitamin B6, Folic acid” and “Amlodipine besylate and folic acid”.

Its studies are mostly in Hypertension · Arthritis, Rheumatoid · Vitamin B 12 Deficiency · Hypophosphatasia · Essential Hypertension, led by 4 companies.

Drug pageFolic Acid: every studyAll 180 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 19, 200810 company-led studies, 2 open or runningNext primary completion: Jun 30, 2029 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen Ausa Pharmed52 open or runningphase 4since Nov 19, 2008Nov 19, 2008Jun 30, 2029phase 4 · NCT04974151
Johnson & Johnsonits history only30 open or runningphase 1since Jun 30, 2008Jun 30, 2008none ahead
AstraZenecaits history only10 open or runningphase 4since Aug 23, 2023Aug 23, 2023none ahead
Celltrionits history only10 open or runningphase 1since May 22, 2013May 22, 2013none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Shenzhen Ausa Pharmed only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2008First study: phase 4 study in Essential HypertensionFirst studyNCT00794885 · 20,702 enrolled · China
  2. May 29, 2013Phase 4 study in HypertensionNCT01871740 · China
  3. Mar 14, 2018Phase 4 study in HypertensionNCT03472508 · 3,600 enrolled · China
  4. Jul 13, 20212 phase 4 studies in HypertensionNCT04974151, NCT04974138

Ahead

  1. Jun 30, 2029Primary completion: phase 4 study in HypertensionNCT04974151
  2. Jun 30, 2030Primary completion: phase 4 study in HypertensionNCT04974138

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 Shenzhen Ausa Pharmed leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04974151Hypertension · China4RecruitingJun 30, 202924,000
NCT04974138Hypertension · China4RecruitingJun 30, 203032,000
NCT03472508Hypertension · China4UNKNOWNMar 30, 20193,600
NCT01871740Hypertension · China4WithdrawnJun 20140
NCT00794885Essential Hypertension · China4CompletedAug 201320,702

How it is read

Names in the registry

  • “Folic Acid”, 2 entries
  • “Norgestimate; Ethinyl Estradiol; Folic acid”, 2 entries
  • “Vitamin B12, Vitamin B6, Folic acid”, 1 entry
  • “Amlodipine besylate and folic acid”, 1 entry
  • “Amlodipine besylate And Folic Acid”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.